About Verge Genomics
Verge Genomics develops drugs for severe diseases like ALS, Parkinson's Disease, and Frontotemporal Dementia using human genomics and machine learning. Instead of traditional animal models, they create a large database of human tissue to better understand disease causes. Their AI platform, CONVERGE®, helps analyze this data to identify potential drug candidates. Their first drug, VRG50635, is already in clinical trials for ALS, showcasing their ability to quickly transition from research to clinical application. Verge Genomics aims to provide effective treatments for patients and generate revenue through the successful commercialization of their drug candidates.
South San Francisco, CaliforniaHeadquarters
2015Year Founded
$130.5MTotal Funding
SERIES_BCompany Stage
AI & Machine Learning, BiotechnologyIndustries
51-200Employees
Benefits
Excellent medical, dental, and vision coverage
401(k) plan with employer matching for contributions
Disability insurance, Life insurance, Dependant Care FSA and Healthcare FSA
Unlimited paid time off
Paid parental leave
Access to free onsite fitness center
Free snacks and lunch for employees who work onsite
WFH stipend for employees who work remotely
Risks
Increased competition from AI-driven bioinformatics companies like Synthace.
Reliance on partnerships may pose risks if collaborations don't yield successful outcomes.
Regulatory scrutiny on digital devices in trials could delay progress.
Differentiation
Verge Genomics uses AI and human genomics for drug discovery, unlike traditional methods.
Their CONVERGE® platform accelerates drug development from research to clinic in four years.
They focus on neurodegenerative diseases, using a proprietary multi-omics database for insights.
Upsides
Partnerships with Eli Lilly and AstraZeneca enhance drug discovery and development efforts.
Digital biosensors in trials improve data accuracy and patient monitoring remotely.
Collaboration with Stem Pharm accelerates validation of novel drug targets for Parkinson's.
Funding
Total raised$130.46 M
Latest valuation$490.00 M
StageSERIES_B
SERIES A
6/30/2018$32
$160.00 M